Table 2.
Response Assessment and Time to Treatment Failure in the First, Second, and Third Lines
| n | n - SD / PR / PD / NE | Time to Failure, Median (95% CI) | |
|---|---|---|---|
| First-line | 23 | 7 / 2 /10 /4 | 3.8 mo (3.2–8.7) |
| Sorafenib | 9 | 1 / 0 / 4 / 4 | 7.8 mo (1.2-NA) |
| Capecitabine | 7 | 2 / 1 / 4 / 0 | 3.2 mo (0.4-NA) |
| IFN plus capecitabine | 3 | 2 / 1 / 0 / 0 | 4.0 mo (3.5-NA) |
| GemOX | 1 | 1 / 0 / 0 / 0 | NA |
| Cisplatin plus capecitabin | 1 | 0 / 0 / 1 /0 | NA |
| Cisplatin plus doxorubicin | 1 | 1 / 0 / 0 / 0 | NA |
| Cisplatin | 1 | 0 /0 /1 / 0 | NA |
| Second-line | 19 | 5 /5 / 8 /1 | 3.5mo (1.5–11.6) |
| IFN plus capecitabine | 8 | 1 /1 / 5 / 1 | 3.5 mo (2.7-NA) |
| mFLOX | 3 | 0 / 2/ 1 / 0 | NA |
| GemOX | 3 | 1 /1 /1 /0 | 6.8 mo (3.6-NA) |
| GemCis | 2 | 1 /1 / 0 / 0 | 8.7 mo (NR-NA) |
| Doxorubicin | 2 | 1 / 0 / 1 /0 | 1.4 mo (NR-NA) |
| Cisplatin plus capecitabine | 1 | 1 / 0 / 0 /0 | NA |
| Third-line | 12 | 3 / 1 / 6 / 2 | 2.4 mo (1.1–22) |
| Doxorubicin | 3 | 1 /0 /2 / 0 | 1.7 mo (1.4-NA) |
| GemOx | 3 | 1 /1 /1 / 0 | 5.1 mo (2.4-NA) |
| mFLOX | 1 | 0 / 0 / 1 / 0 | 2.7 mo (NA-NA) |
| Gemcitabine | 2 | 1 / 0 / 1 / 0 | 1.4 mo (NA-NA) |
| Others | 3 | 0 / 0 / 1 / 2 | NA |
Abbreviations: SD, stable disease; PR, partial response; PD, progressive disease; NE, non-evaluable; NA, not-achieved; CI, confidence interval.